-
Mashup Score: 5
A pair of recent studies from the laboratory of Bin Zhang, MD, PhD, the Johanna Dobe Professor of Cancer Immunology, have uncovered new details about critical immunological processes that may help improve cancer treatments, according to the findings.
Source: news.feinberg.northwestern.eduCategories: General Medicine NewsTweet
-
Mashup Score: 0
What’s new? Neurological immune-related adverse events from immune checkpoint inhibitor therapy are rare, but potentially life-threatening. Here, the authors identified serum neurofilament light chai…
Source: onlinelibrary.wiley.comCategories: General Medicine NewsTweet-
NOW ONLINE! New research identifies NFL and GFAP as promising biomarkers for neurological immune-related adverse events from immune checkpoint therapy. #Immunotherapy 🔓OPEN ACCESS ➡️https://t.co/gFrcaeiXEe https://t.co/hkRFYaokLE
-
-
Mashup Score: 28
KEYNOTE-689 marks the first positive trial in more than two decades for patients with resected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) Results to be presented at American Association for Cancer Research (AACR) Annual Meeting 2025 during a Plenary Session and included in official meeting press program Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, as a perioperative treatment regimen for patients with stage III or IVA, resected, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Results at the first interim analysis of the trial showed KEYTRUDA significantly improved event-free survival (EFS) as part of a perioperative treatment regimen with adjuvant standard of care (SOC) radiotherapy with or without cisplatin compared to adjuvant standard of care (SOC) radiotherapy with or without cisplatin
Source: www.merck.comCategories: General Medicine NewsTweet-
Today, we presented new data from a Phase 3 trial of our #immunotherapy in earlier stages of head and neck cancer. These data were presented during the AACR press program. Learn more here: https://t.co/HLMo9deenh https://t.co/MCxpAqlF4r
-
-
Mashup Score: 7
Immunai will generate a publicly accessible multi-omic dataset for a Parker Institute cohort of over 1,000 cancer patients.
Source: www.genengnews.comCategories: General Medicine News, Future of MedicineTweet-
Immunai and Parker Institute to Build Massive Cancer Single-Cell Dataset Immunai will generate a publicly accessible multi-omic dataset for a cohort of over 1,000 patients treated with standard-of-care #immunotherapy from the @parkerici. https://t.co/ewAuuDo3a3
-
-
Mashup Score: 14The aryl hydrocarbon receptor controls IFN-γ-induced immune checkpoints PD-L1 and IDO via the JAK/STAT pathway in lung adenocarcinoma - 1 month(s) ago
Abstract. While immunotherapy has shown some efficacy in lung adenocarcinoma (LUAD) patients, many respond only partially or not at all. One limitation in
Source: academic.oup.comCategories: General Medicine NewsTweet-
Research linked the AhR, an environmental chemical receptor implicated in lung cancer, to IFN-gamma-induced JAK/STAT pathway and immune checkpoint-mediated immunosuppression indicating a new target for lung adenocarcinoma patient #immunotherapy. Read more: https://t.co/vLJlXvxu9B https://t.co/1APbIUIjnu
-
-
Mashup Score: 39Pembrolizumab in Patients with Advanced Miscellaneous Rare Cancers: Results from a Phase 2 Basket Trial - 2 month(s) ago
ABSTRACTIntroduction. Rare solid tumors account for one-quarter of cancers among adults in the United States, but few resources have been devoted to their treatment. We evaluated the efficacy of pembrolizumab, a programmed cell death-1 inhibitor, in patients with rare solid tumors.Methods. We conducted a phase 2 basket trial that included patients with rare, advanced tumors. Patients were enrolled in the study in nine tumor-specific and a 10th cohort of miscellaneous rare histologies. Patients received pembrolizumab 200 mg intravenously every 21 days. The primary endpoint was the non-progression rate at 27 weeks per immune-related Response Evaluation Criteria in Solid Tumors (RECIST). The secondary endpoints were confirmed objective response (immune-related complete response [irCR] or partial response [irPR]), clinical benefit (irCR, irPR, or immune-related stable disease [irSD] ≥ 4 months), safety, and tolerability. Pretreatment biopsy specimens were examined for programmed cell death
Source: meridian.allenpress.comCategories: General Medicine NewsTweet-
⭐️Nice to see this published 👉🏼 #Immunotherapy in some of the rarest of the rare tumors 👉🏼Pembrolizumab in Patients with Advanced Miscellaneous Rare Cancers: Results from a Phase 2 Basket Trial @mirella_nardo @ANaingMD 👏🏼👏🏼👏🏼 @DavidHongMD @OncoAlert https://t.co/7Hp6WgaVru
-
-
Mashup Score: 0
Black patients with metastatic triple-negative breast cancer received immunotherapy less frequently than patients of other racial or ethnic backgrounds, according to results of a retrospective cohort study.However, patients who received immunotherapy achieved similar survival outcomes regardless of race or ethnicity.
Source: www.healio.comCategories: General Medicine NewsTweet-
📉 Data from a retrospective study in @JAMANetworkOpen show that Black patients with metastatic triple-negative breast cancer received #immunotherapy less often than white patients, despite having similar survival outcomes regardless of race/ethnicity. https://t.co/rGRLBNq4Ow
-
-
Mashup Score: 89Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial - 2 month(s) ago
Nature Medicine – In an iterative phase 2 trial, patients with metastatic, treatment-refractory, mismatch repair proficient gastrointestinal cancers had responses to neoantigen-reactive…
Source: www.nature.comCategories: General Medicine NewsTweet-
Today @NatureMedicine! 🗞️ TILs Tumor Infiltrating Lymphocytes🔴🟠🟢 ➖a cell-based therapy for patients with colorectal & GI cancers➡️#immunotherapy. Responses➕“survivors” ➡️black arrows. 4️⃣>48-month survival ≈ CURES. Pembro⬆️responses. @OncoAlert https://t.co/2wLWqA8E23 https://t.co/1WbMGHQJqT
-
-
Mashup Score: 5Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial - 2 month(s) ago
Nature Medicine – In an iterative phase 2 trial, patients with metastatic, treatment-refractory, mismatch repair proficient gastrointestinal cancers had responses to neoantigen-reactive…
Source: www.nature.comCategories: General Medicine NewsTweet-
Today @NatureMedicine! 🗞️ TILs Tumor Infiltrating Lymphocytes🔴🟠🟢 ➖a cell-based therapy for patients with colorectal & GI cancers➡️#immunotherapy. Responses➕“survivors” ➡️black arrows. 4️⃣>48-month survival ≈ CURES. Pembro⬆️responses. @OncoAlert https://t.co/2wLWqA8E23 https://t.co/1WbMGHQJqT
-
-
Mashup Score: 0Immune cell discovery offers new potential for cancer immunotherapy | Winship Cancer Institute of Emory University - 2 month(s) ago
Winship led study reveals a new AI-based computational pathology tool designed to better manage treatment for patients with ductal carcinoma in situ (DCIS), a form of pre-invasive breast cancer.
Source: winshipcancer.emory.eduCategories: General Medicine News, Oncologists1Tweet-
In a study funded by NCI's Division of Cancer Biology, researchers @EmoryMedicine discovered a 🆕 type of immune cell that controls anti-tumor immunity and may play a role in responses to #immunotherapy. https://t.co/FjQlFMp9c4
-
A pair of recent studies from the lab of @BinZhang_NU @LurieCancer have uncovered new details about critical biological processes that may help improve cancer treatments. https://t.co/GmxljnCHNS @immunology_nu #immunotherapy